24/7 Market News Snapshot 05 February, 2025 – Adicet Bio, Inc. Common Stock (NASDAQ:ACET)

February 5, 2025

DENVER, Colo., 05 February, 2025 (247marketnews.com) – (NASDAQ:ACET) are discussed in this article.
Adicet Bio, Inc. (NASDAQ:ACET) is experiencing a notable surge in market activity, with shares trading at $1.129, marking an impressive 22.73% increase from the previous close of $0.920. This uptick in pre-market trading comes alongside a robust trading volume of 1.36 million shares, signaling heightened investor interest and optimism regarding the company’s future prospects within the biotech sector.

In addition to the positive market response, Adicet Bio has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy, ADI-001, aimed at treating adult patients with refractory systemic lupus erythematosus (SLE) exhibiting extrarenal involvement. Fast Track Designation is granted to therapies that address serious health conditions and fulfill unmet medical needs, expediting their development and review processes.

ADI-001 is an innovative allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy designed specifically to target CD20, representing a significant advancement in the treatment landscape for autoimmune diseases. The therapy’s versatility is highlighted by its earlier Fast Track Designation concerning relapsed/refractory class III or class IV lupus nephritis, underscoring its potential effectiveness against complex autoimmune disorders.

Adicet Bio’s strategic initiatives are focused on advancing its clinical pipeline, with ongoing enrollment in a Phase 1 trial assessing the efficacy of ADI-001 in lupus nephritis. The company anticipates commencing enrollment for additional indications, including systemic sclerosis, idiopathic inflammatory myopathy, and stiff person syndrome, by early 2025, with plans to expand into other areas later in the year.

With its innovative approach to immunotherapy through “off-the-shelf” gamma delta T cells, Adicet Bio is set to make significant strides in improving patient outcomes for those wrestling with autoimmune diseases and cancer, reaffirming its commitment to enhancing the field of healthcare.

Related news for (ACET)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.